Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 12/20 | 0.46 |
| ▸ | BRD9 | Q9H8M2 | 3/20 | 0.45 |
| ▸ | BRD7 | Q9NPI1 | 3/20 | 0.45 |
| ▸ | TAF1 | P21675 | 2/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.45 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.45 |
| ▸ | CECR2 | Q9BXF3 | 2/20 | 0.45 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.45 |
| ▸ | BPTF | Q12830 | 1/20 | 0.45 |
| ▸ | TAF1L | Q8IZX4 | 1/20 | 0.45 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.45 |
| ▸ | ATAD2B | Q9ULI0 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | ACVR2B | Q13705 | 1/20 | 0.44 |
| ▸ | BRD8 | Q9H0E9 | 1/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21224912 | 0.93 | BRD4 (0.45) | BRD4BRD9BRD7TAF1TGFBR1 | |
| SCHEMBL22306886 | 0.79 | BRD4 (0.46) | BRD4BRD9BRD7TAF1TGFBR1 | |
| SCHEMBL23783324 | 0.79 | HASPIN (0.49) | BRD4BRD9BRD7TAF1TGFBR1 | |
| SCHEMBL21917257 | 0.79 | AXL (0.40) | BRD4BRD9BRD7TAF1TGFBR1 | |
| SCHEMBL21224811 | 0.78 | BRD4 (0.37) | BRD4BRD9BRD7 | |
| SCHEMBL23122675 | 0.77 | CNR1 (0.41) | BRD4AXLKAT2BADORA3ADORA2A | |
| SCHEMBL24556448 | 0.77 | BRD4 (0.46) | BRD4BRD9BRD7TAF1TGFBR1 | |
| SCHEMBL24556402 | 0.77 | BRD4 (0.44) | BRD4BRD9BRD7TAF1TGFBR1 | |
| SCHEMBL19869619 | 0.77 | BRD4 (0.44) | BRD4BRD9BRD7TAF1TGFBR1 | |
| SCHEMBL2877666 | 0.77 | DYRK1A (0.59) | TGFBR1AXLNFATC1GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384776-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4134364-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2025-07-30 | — | — | EP | disclosed |
| CN-119823124-A | Compounds for targeted degradation of BRD9 | C4医药公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20250084081-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | US | disclosed |
| CN-119504743-A | Naphthyridones compound, pharmaceutical composition and application thereof | 中国药科大学 | 2025-02-25 | — | — | CN | disclosed |
| CN-115279370-B | Compounds for targeted degradation of BRD9 | C4医药公司 | 2025-01-10 | — | — | CN | disclosed |
| US-12157735-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2024-12-03 | — | — | US | disclosed |
| CN-118619937-A | Benzotriazine double oxide and pharmaceutical composition thereof | 浙江瑞臻医药有限公司 | 2024-09-10 | — | — | CN | disclosed |
| US-12049464-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-20150183784-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-07-02 | — | — | US | disclosed |
| US-20150183784-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-07-02 | — | — | US | disclosed |
| US-9034900-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034900-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034900-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-04-23 | — | — | US | disclosed |
| WO-2015058160-A1 | BROMODOMAIN INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2015-04-23 | — | — | WO | disclosed |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-04-23 | — | — | US | disclosed |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-04-23 | — | — | US | disclosed |
| WO-2015058160-A1 | BROMODOMAIN INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384776-B2 | Compounds and uses thereof | VHL, TFEB, BECN1 | BRD4 42/4885BRD9 290/4885BRD7 149/4885 |
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885BRD9 19/4885BRD7 14/4885 |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885BRD9 19/4885BRD7 14/4885 |
| US-12157735-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | BRD4 30/4885BRD9 1/4885BRD7 8/4885 |
| US-12049464-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | BRD4 30/4885BRD9 1/4885BRD7 8/4885 |
| US-20150183784-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885BRD9 19/4885BRD7 14/4885 |
| US-20250084081-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | BRD4 30/4885BRD9 1/4885BRD7 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.